A Pilot Study of Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Acalabrutinib (Primary) ; Bendamustine; Cytarabine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 30 Nov 2018 Planned End Date changed from 31 Dec 2025 to 30 Nov 2025.
- 30 Nov 2018 Planned primary completion date changed from 30 Jun 2021 to 31 May 2021.
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.